Clinical Guides
Malaria: Diagnosis, Severity and Safe Referral
Malaria is a parasitic febrile illness in which prompt parasitological confirmation, species-aware interpretation, recognition of severe disease and a reliable referral plan are more important than a memorised drug schedule.
MedNext Academy | 14 min read
Malaria: Diagnosis, Severity and Safe Referral
Malaria is a parasitic febrile illness in which prompt parasitological confirmation, species-aware interpretation, recognition of severe disease and a reliable referral plan are more important than a memorised drug schedule.
Summary
Malaria is caused by Plasmodium parasites transmitted mainly by infected Anopheles mosquitoes. In India, P. falciparum and P. vivax are the clinically dominant species, but mixed infection and less common species occur. The immediate clinical task is to decide whether a person with fever could have malaria, obtain a reliable parasitological test without dangerous delay, identify severe malaria or another emergency, and arrange treatment through the current local pathway. Fever periodicity is neither sufficiently sensitive nor sufficiently specific to diagnose or exclude it.
Species matters because P. falciparum can progress rapidly to severe malaria and because P. vivax and P. ovale have dormant liver forms that create relapse risk. Severity matters more urgently than species: impaired consciousness, respiratory distress, shock, severe anaemia, renal impairment, hypoglycaemia, acidosis, bleeding, jaundice with other organ dysfunction, haemoglobinuria or high parasite density require hospital-level assessment and parenteral treatment capability. A patient can deteriorate despite a modest-looking fever chart.
Uncomplicated malaria is a confirmed infection without severe features in a person able to take and absorb oral treatment. Its regimen depends on species, geographic resistance patterns, age or weight, pregnancy, G6PD status where radical cure is considered and current national or state policy. This draft deliberately does not reproduce a district prescription table. WHO guidance is global; the Indian NCVBDC documents cited here are official but older and must be checked against the current programme instruction before a regimen is chosen.
How Common Is It?
Malaria risk is geographically and seasonally uneven. It is shaped by rainfall, vector habitat, housing, migration, forest or border travel, access to testing and the effectiveness of surveillance and vector control. Clinic case counts cannot be compared casually across districts because testing intensity, reporting, private-sector notification and outbreak response differ. A declining state-level total does not make malaria impossible in a traveller or resident from a local focus, and a high-incidence label does not make every fever malaria.
India’s National Framework for Malaria Elimination 2016–2030 describes elimination as a phased programme requiring surveillance, prompt diagnosis and treatment, vector control and response to local transmission. It also records that P. falciparum and P. vivax distributions differ between settings. The document is a national programme framework rather than a current individual-treatment label, so it supports public-health context but should not be used to infer today’s district regimen or incidence. The WHO guideline likewise deliberately updates recommendations over time; its 13 August 2025 edition supersedes earlier consolidated versions.
At the bedside, the meaningful prevalence question is exposure probability: where the person stayed, whether local transmission was present, the timing of fever relative to travel, overnight vector exposure, prophylaxis where relevant and whether others in the household or work group are ill. Epidemiology sets a testing threshold; it never removes the need to examine for sepsis, dengue, enteric fever, leptospirosis, viral illness, pneumonia, urinary infection, meningitis and non-infectious causes of fever.
Risk Factors
Exposure risk increases with residence in or travel to a transmission area, night-time outdoor work, forest fringe exposure, inadequate vector protection, insecure housing, migration and delayed access to diagnosis. Infants and young children, pregnant people, people without recent immunity, older adults and those with significant comorbidity may become severely ill with less physiological reserve. Immunosuppression, splenectomy and poor access to fluids or emergency transport can compound risk, but none should be used to dismiss symptoms in an otherwise healthy adult.
Species and relapse risk must be separated. P. vivax and P. ovale can form hypnozoites that later reactivate, whereas P. falciparum does not form hypnozoites. Relapse is therefore not proof of treatment non-adherence or reinfection without species and exposure review. Radical-cure medicines can cause dangerous haemolysis in G6PD deficiency and have pregnancy- and age-specific restrictions; eligibility requires a current protocol and reliable testing or specialist advice. A person who has had malaria before can still acquire a new infection.
Drug resistance is a programme and clinical concern, not a reason for unsupervised switching between antimalarials. Apparent failure may reflect wrong diagnosis, vomiting, poor absorption, under-dosing, counterfeit or poor-quality medicines, non-adherence, reinfection or parasite resistance. WHO recommends country programmes use surveillance and updated guidance; India’s older national policy explicitly noted regional variation in partner-drug choice. This makes exact location, medicine history, formulation, dose dates and vomiting history clinically important.
Diagnosis
History
Ask about fever onset and pattern, rigors, headache, myalgia, vomiting, diarrhoea, confusion, seizures, breathlessness, reduced urine, bleeding, jaundice, dark urine and oral intake. Establish every location visited in the previous month, dates, overnight stays, forest or border exposure, mosquito prevention, previous malaria, chemoprophylaxis and contacts with similar fever. Record pregnancy, gestation, infant age or weight, chronic disease, immunosuppression and all medicines. A precise timeline prevents a vague travel history from becoming false reassurance or false certainty.
Examination
Measure temperature, pulse, blood pressure, respiratory rate, oxygen saturation, capillary refill, mental state and glucose early. Look for altered consciousness, prostration, repeated vomiting, respiratory distress, dehydration, jaundice, pallor, bleeding, shock, hepatosplenomegaly and focal infection. Assess for meningism, rash, eschar, pulmonary signs, abdominal tenderness and urinary findings that may indicate another diagnosis. In a child, inability to drink, lethargy, seizure and respiratory effort are high-consequence signs. Normal examination between fever spikes does not exclude malaria.
Investigations
Test suspected malaria promptly with quality-assured microscopy and/or a rapid diagnostic test (RDT), according to local availability. Microscopy can identify species, estimate parasitaemia and detect mixed infection when performed and read well; RDTs offer timely antigen detection but have species and post-treatment limitations. A negative result in a highly plausible presentation needs clinical reassessment and repeat testing according to local protocol, not blind repeated treatment. For confirmed or severe illness, obtain blood count, glucose, renal and liver function, acid-base or lactate assessment where available, blood group and crossmatch when anaemia is significant, and tests directed at co-infection or an alternative diagnosis. Never delay referral for severe disease while awaiting a smear.
Differential Diagnosis
Malaria is a fever syndrome, not a default label for anyone with travel history. In India, dengue, enteric fever, leptospirosis, scrub typhus, acute viral infections, COVID-19 where circulating, influenza, pneumonia, urinary infection, tuberculosis, meningitis and sepsis may present with fever, headache, myalgia, thrombocytopenia or transaminitis. A positive malaria test does not automatically exclude another process, particularly when focal signs, shock out of proportion to parasitaemia, persisting fever or an atypical course is present. Coinfection is possible.
For a confirmed infection, distinguish uncomplicated disease from severe malaria using physiological and laboratory criteria rather than the apparent ability to sit in the clinic. Severe anaemia, hypoglycaemia and acidosis may occur before dramatic fever. Cerebral malaria requires exclusion of hypoglycaemia, meningitis, encephalitis, seizure-related postictal state and toxic-metabolic causes of coma. Dark urine may indicate haemoglobinuria, rhabdomyolysis or other renal pathology; jaundice may be malaria-associated or viral, hepatobiliary or haemolytic disease.
Species assignment also needs caution. RDT antigen patterns can suggest species but should not be treated as a complete parasite census; microscopy quality, recent treatment and mixed infection matter. Recurrent fever after treatment can be relapse, recrudescence, reinfection, an alternative illness or inadequate drug exposure. These labels have different implications for investigation, notification and programme reporting. Do not call treatment failure until diagnosis, administration, vomiting, absorption, dosing and follow-up tests have been reviewed by a clinician who knows the current local policy.
Management
Manage the person, not the test result alone. For a stable person with confirmed uncomplicated malaria, select treatment from the current national, state or institutional species-specific protocol after checking age or weight, pregnancy, G6PD status when relevant, renal or hepatic impairment, ability to absorb oral medicine and recent antimalarial exposure. Give clear written instructions, explain what vomiting or a missed dose means in that protocol, arrange follow-up and provide a route for rapid return. Confirmed infection should be notified and linked to the local surveillance programme where required.
For suspected severe malaria, start emergency assessment, secure airway, breathing and circulation, check glucose, establish intravenous access, collect urgent samples if doing so does not delay care, and transfer or admit to a facility with parenteral antimalarial treatment, monitoring and critical-care support. WHO recommends parenteral artesunate for severe malaria across species, followed by completion of an appropriate oral regimen when the person can tolerate it; exact dosing, preparation and post-treatment follow-up must follow the current authorised protocol. Avoid fluid overloading: shock needs expert resuscitation, but pulmonary oedema risk and repeated clinical reassessment matter.
Supportive care is specific, not generic. Treat hypoglycaemia, seizures, severe anaemia, acute kidney injury, acidosis and bacterial sepsis when present using local emergency pathways. Do not delay antibiotics if sepsis remains plausible after cultures where feasible. A falling parasite count is reassuring only alongside clinical improvement. Persistent vomiting, new confusion, breathlessness, oliguria or inability to take treatment changes the level of care. Antipyretics improve comfort but do not treat parasites or exclude deterioration.
Prescribing Information
There is no safe universal malaria prescription. Drug selection is species-, severity-, resistance-, age/weight-, pregnancy-, G6PD- and locality-dependent. WHO 2025 guidance provides global recommendations; national programmes translate them into country protocols. The NCVBDC diagnosis-and-treatment guide and National Drug Policy available online describe older Indian regimens and regional resistance considerations. They are useful for understanding why a confirmed species and local programme contact matter, but a prescriber must verify the current district or state instruction, authorised product information and current stock before writing an order.
Do not use oral therapy as a substitute for parenteral treatment and monitored admission in severe malaria. For uncomplicated P. vivax or P. ovale, prevention of relapse requires an assessment for radical cure; primaquine or tafenoquine decisions require current protocol, pregnancy and breastfeeding review, age/weight criteria, G6PD status and counselling about haemolysis. WHO advises against 8-aminoquinolines in pregnancy, breastfeeding an infant with unknown G6PD status, infants and people with G6PD deficiency. The exact test threshold, regimen and follow-up belong to the governing programme.
Before administering any antimalarial, document the test result, species if available, severity screen, weight, pregnancy status, allergies, prior doses, vomiting and concurrent medicines. Observe or arrange supervised treatment when adherence, literacy, vomiting or access make error likely. Review QT-prolonging combinations and cardiotoxicity risk where the selected local regimen requires it. Artemisinin monotherapy is not a responsible substitute for recommended combination treatment. Escalate suspected resistance or failure through the district malaria system rather than improvising a salvage regimen.
When to Refer
Refer immediately to hospital or a higher-level facility for any suspected or confirmed severe malaria, altered consciousness, seizure, respiratory distress, shock, repeated vomiting preventing oral treatment, hypoglycaemia, severe anaemia, jaundice with illness, acute kidney injury, haemoglobinuria, bleeding, acidosis or inability to maintain safe observation. Referral is urgent even if microscopy is unavailable, the RDT is pending or the fever temporarily falls. Call ahead where possible, document time of last oral dose and results, give time-critical emergency treatment only within local authority and do not make transport wait for laboratory paperwork.
Pregnant people, young children, frail older adults and people with significant comorbidity need a low threshold for specialist or hospital assessment because deterioration and medication constraints are more consequential. Pregnancy changes both malaria risk and the available drug options; a current obstetric and malaria protocol must be used. A child who is unable to drink, has persistent vomiting, lethargy, convulsions, respiratory effort or poor perfusion needs urgent paediatric assessment.
Refer to infectious disease, internal medicine, paediatrics, obstetrics, travel medicine or the district malaria officer as appropriate for mixed species, uncertain microscopy, recurrent infection, suspected treatment failure, G6PD-related radical-cure uncertainty, severe adverse drug effects or programme notification questions. Referral quality improves when it includes travel map, test images or reports, drug names and times, weight, pregnancy details, G6PD result with method and the reason a local protocol could not be followed.
Red Flags
New confusion, drowsiness, coma, repeated seizures, inability to sit or drink, respiratory distress, oxygen desaturation, circulatory collapse, cold extremities, persistent vomiting, severe weakness, oliguria, dark urine, spontaneous bleeding or rapidly deepening jaundice are emergency signs in a person with possible malaria. Check bedside glucose immediately in altered mental status, seizures, pregnancy and children; hypoglycaemia is treatable but can coexist with severe malaria. Do not attribute coma to a positive RDT without considering meningitis, encephalitis, severe sepsis, toxic exposure, stroke and metabolic disease.
Any fever in pregnancy after relevant exposure merits same-day clinical assessment. Pregnancy is not a reason to defer testing or to use an unverified regimen; the medicine choice and level of monitoring require current obstetric-malaria guidance. In children, poor feeding, lethargy, irritability, difficult breathing, repeated vomiting or a seizure should trigger emergency review even if a caregiver reports that the fever is lower after paracetamol. In older or immunocompromised adults, delirium, falls and reduced intake may be the initial signal of serious illness.
A negative initial test is not a licence to ignore deterioration. If exposure and symptoms remain credible, re-examine, repeat testing as directed locally and investigate alternatives. The red flag is physiology, not a parasite number alone. Conversely, a positive test in a stable person does not protect them from a separate emergency such as dengue shock, bacterial sepsis or an ectopic pregnancy. Maintain reassessment and escalation instructions in writing.
Indian Clinical Context
India’s malaria control architecture is led by the National Centre for Vector Borne Diseases Control (NCVBDC). The National Framework for Malaria Elimination in India 2016–2030 describes elimination, surveillance and focal response as programme functions. Local transmission, parasite mix, RDT availability, microscopy quality, referral distance and antimalarial policy vary across and within states. A safe clinician checks the current NCVBDC, state and institutional instruction rather than assuming that a table from a 2013 policy PDF remains the current regimen everywhere.
The official NCVBDC documents available online establish several durable principles: investigate suspected malaria with microscopy and/or RDT, differentiate species where possible, act early and refer severe disease. They also illustrate why resistance caveats matter: the 2013 policy described a different partner-drug approach in north-eastern states. This guide intentionally does not reproduce those dated doses or make a claim about present resistance. If treatment failure is suspected, document dosing and vomiting, exclude reinfection or another diagnosis and contact the district or state malaria programme for current advice and reporting.
Counselling should be practical: identify the nearest facility able to test and admit, explain that private and public care should connect to surveillance, use locally understood danger-sign language and engage family for transport and follow-up. Bed nets, vector control and prompt testing are preventive systems, not an alternative to urgent care. Migrant workers, forest communities and people with limited phone access need an explicit return plan. This guide does not claim uniform availability of microscopy, G6PD testing, parenteral artesunate or intensive care across India.
NMC Competency Mapping
Malaria is an integrated exercise in microbiology, medicine, pharmacology, paediatrics, obstetrics and community medicine. The NMC CBME Curriculum 2024 establishes the competence-based curricular framework; this guide maps learning activities to that framework without inventing a specific code from memory. Learners should be able to elicit a geographically precise exposure history, recognise a potentially life-threatening fever syndrome, request and interpret microscopy or RDT within its limits, and communicate a referral decision clearly.
At the knowledge level, distinguish P. falciparum from relapse-forming P. vivax or P. ovale, uncomplicated from severe malaria, microscopy from antigen testing and relapse from reinfection or recrudescence. At know-how level, build a differential for fever with thrombocytopenia, identify why a negative initial test may need reassessment and recognise pregnancy, G6PD deficiency and child weight as prescribing constraints. At show-how level, demonstrate a severity screen, check glucose, communicate danger signs and hand over a referral with times, results and medicines accurately.
Assessment should test clinical judgement. A forest traveller with fever and a negative first RDT tests iterative diagnosis; a confused person with parasitaemia tests emergency referral; a pregnant patient tests medicine safety and protocol verification; recurrent vivax infection tests relapse reasoning and G6PD caution. Answers should lose credit when they quote a regimen without species, severity, age/weight, pregnancy and local-resistance context. Programme claims should cite NCVBDC sources and acknowledge date limits rather than presenting old policy as timeless truth.
Key Exam Pearls for NEET PG
Malaria diagnosis requires parasitological confirmation where testing is available, but severe-malaria referral must not wait for a perfect smear. Microscopy can identify species, mixed infection and parasite density when quality is good; RDTs accelerate detection but do not remove their antigen and species limitations. P. falciparum has the greatest severe-disease urgency, yet severe malaria may occur with any species and severity is defined by organ dysfunction or dangerous physiology, not by fever height.
P. vivax and P. ovale can relapse because of liver hypnozoites. Radical cure therefore raises G6PD, pregnancy, breastfeeding, infant and protocol questions; it is not simply another tablet added to every positive test. Primaquine and tafenoquine can precipitate haemolysis in G6PD deficiency. Recurrent fever may represent relapse, recrudescence, reinfection, wrong diagnosis, inadequate absorption or resistance; the distinction needs species, exposure, treatment and follow-up data.
In India, remember the programme principle rather than a possibly dated tablet table: test early, identify species, treat according to current official local policy and refer severe disease. The online NCVBDC 2013 policy documented regional regimen differences, which is itself a clue that resistance geography matters. Pregnancy and paediatric malaria require verified current protocols. In an exam vignette, altered sensorium, seizures, shock, respiratory distress, hypoglycaemia, severe anaemia, renal failure, acidosis or haemoglobinuria should move the answer toward emergency management and parenteral-treatment capability.
Frequently Asked Questions
Can a negative rapid diagnostic test safely exclude malaria after travel?
Not always. A negative RDT lowers the probability of malaria, but its interpretation depends on timing, test quality, species, parasite density and pre-test likelihood. If exposure and symptoms remain credible, a clinician should reassess the person, arrange microscopy or repeat testing according to the local protocol, and investigate alternative causes of fever. A deteriorating patient needs emergency assessment regardless of the first test result. Repeated empirical antimalarial treatment without reassessment can delay diagnosis of sepsis, dengue, meningitis or another serious condition.
Why are P. vivax and P. falciparum managed differently after confirmation?
P. falciparum has a high propensity for rapid severe disease and requires prompt severity assessment. P. vivax can also be serious, but it may leave dormant liver forms that cause later relapse. Preventing relapse requires consideration of radical cure, which is constrained by G6PD status, pregnancy, breastfeeding, age or weight and current national policy. Those differences mean a laboratory species result changes the questions the prescriber must answer; it does not give a safe universal regimen without local protocol review.
What should a pregnant person with fever and malaria exposure do?
Seek same-day medical assessment for malaria testing and evaluation of other causes of fever. Pregnancy increases the consequences of malaria and changes which antimalarials and relapse-prevention medicines are appropriate. Do not self-start old tablets, borrowed medicines or an online regimen. The clinician should assess severity, gestation, ability to take oral treatment and current local malaria and obstetric guidance. Urgent symptoms such as confusion, breathlessness, collapse, repeated vomiting, bleeding or reduced fetal movement require emergency care.
Does fever returning after treatment prove antimalarial drug resistance?
No. Recurrence can represent relapse, reinfection, recrudescence, inadequate dose, vomiting or poor absorption, non-adherence, a wrong initial diagnosis or a separate illness. Resistance is important, but it should be evaluated through the current programme pathway rather than assumed. Bring all medicine packets, test reports and travel dates to review. The clinician may repeat parasitological testing, assess species and severity, check administration and contact the district malaria programme where treatment failure is plausible.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic